New pricing norms may hit pharma cos earnings: ICRA

With the National List of Essential Medicines (NLEM) estimated to cover almost 20 percent of the Rs 72,800 crore domestic formulation business, an expected price cut of 15-20 percent will erode the market by 3-4 percent, the ICRA report said.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Travelcafe
moneycontrol.com

Home » News » Business

May 31, 2013, 08.34 AM | Source: PTI

New pricing norms may hit pharma cos' earnings: ICRA

With the National List of Essential Medicines (NLEM) estimated to cover almost 20 percent of the Rs 72,800 crore domestic formulation business, an expected price cut of 15-20 percent will erode the market by 3-4 percent, the ICRA report said.

Like this story, share it with millions of investors on M3

New pricing norms may hit pharma cos earnings: ICRA

With the National List of Essential Medicines (NLEM) estimated to cover almost 20 percent of the Rs 72,800 crore domestic formulation business, an expected price cut of 15-20 percent will erode the market by 3-4 percent, the ICRA report said.

Post Your Comments

Share Cancel

New pricing norms may hit pharma cos earnings: ICRA
The proposed market-based pricing mechanism for the pharmaceutical industry is expected to impact near term earnings of companies with relatively higher dependence on Indian market, rating agency ICRA said today.

With the National List of Essential Medicines (NLEM) estimated to cover almost 20 percent of the Rs 72,800 crore domestic formulation business, an expected price cut of 15-20 percent will erode the market by 3-4 percent, it said. Its impact on earnings will be higher, as much of this will directly eat into the relatively higher margin India business, ICRA said in a report.

Also read: Not impacted by Ranbaxy's negative news: Alembic Pharma

Companies with higher dependence on the Indian market like Indian arm of MNCs, mid-size pharma companies and greater share of acute therapy segments (like 70 percent of NLEM) will be impacted the most, it added.

Conversely, the impact of the new policy would not be substantial on companies that have sizable share of earnings from regulated markets, especially US generics, it said. The Department of Pharmaceuticals released a detailed note paving the way for the implementation of the proposed pricing policy recently.

In line with the earlier proposal, the policy has adopted a market-based pricing mechanism wherein the ceiling price for each branded drug or a generic version will be determined by taking a simple average of all drugs with market share equal to or greater than 1 percent.

The policy will control prices of 348 drugs that are classified as 'Essential' and form part of the National List of Essential Medicines (NLEM). The companies will be allowed to revise prices of these molecules once a year in line with the change in the Wholesale Price Index (WPI). After the detailed guidelines, the government will notify the ceiling prices, post which the policy will come into effect with 45 days.

Companies will have to adjust their MRPs within this period which would result in some inventory de-stocking in the coming few months by the distribution channel.

Overall, a market-based pricing mechanism is more acceptable to the industry and, over a longer period, it may limit the adverse impact on it though there would be some challenges and uncertainties in its implementation, ICRA said.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
New pricing norms may hit pharma cos earnings: ICRA

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login